GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

deutenzalutamide   Click here for help

GtoPdb Ligand ID: 14402

Synonyms: enzalutamide d3 | enzalutamide-d3 | Hainaan® (China) | HC-1119 | HC1119 | MDV3100-d3
Approved drug
deutenzalutamide is an approved drug
Compound class: Synthetic organic
Comment: Deutenzalutamide (HC-1119) is a deuterium labeled analogue of the non-steroidal androgen receptor (AR) antagonist enzalutamide ([1]).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 108.53
Molecular weight 464.44
XLogP 1.99
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC1(C)C(=O)N(C2=CC=C(C#N)C(=C2)C(F)(F)F)C(=S)N1C3=CC=C(C(=C3)F)C(=O)NC([2H])([2H])[2H]
Isomeric SMILES [2H]C([2H])([2H])NC(=O)C1=C(C=C(C=C1)N2C(=S)N(C(=O)C2(C)C)C3=CC(=C(C=C3)C#N)C(F)(F)F)F
InChI InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)/i3D3
InChI Key WXCXUHSOUPDCQV-HPRDVNIFSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

Bioactivity Comments
Potency as an AR antagonist is unlikely to be significantly different from that of enzalutamide [1].
Selectivity at nuclear hormone receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
Androgen receptor Primary target of this compound Hs Antagonist Antagonist ~7.4 pIC50 - 1
pIC50 ~7.4 (IC50 ~4x10-8 M) [1]
Description: Based on potency of enzalutamide in LNCaP prostate cells